Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$167.36 USD
+0.20 (0.12%)
Updated Sep 4, 2024 04:00 PM ET
Pre-Market: $167.05 -0.31 (-0.19%) 8:32 AM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$167.36 USD
+0.20 (0.12%)
Updated Sep 4, 2024 04:00 PM ET
Pre-Market: $167.05 -0.31 (-0.19%) 8:32 AM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
Zacks News
Top Research Reports for February 1, 2017
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), PayPal (PYPL) and Thermo Fisher (TMO).
Stock Market Roundup Jan. 31: Nasdaq Rebounds Amid Trump Biotech Meeting
by Madeleine Johnson
Following the trend set yesterday, U.S. stocks closed mostly lower on Tuesday but still managed to record monthly gains. Investors continue to weigh the latest policies from the Trump Administration as well as companies' results from the current earnings season.
Biotech Stocks Gain on Latest Trump Drug Price Statements
by Ryan McQueeney
President Trump continues to double down on his campaign promises, and his latest statements regarding drug prices and regulation have sent biotech stocks higher on Tuesday.
Pfizer (PFE) Q4 Earnings Lag, Sales Top; '17 Sales View Soft
by Kinjel Shah
Pfizer, Inc. (PFE) missed earnings estimates in the fourth quarter.
Dow 30 Stock Roundup: Boeing, Caterpillar, Johnson & Johnson, DuPont Beat on Earnings
by Swarup Gupta
The Dow gained over the week following continuing optimism over Trump's first actions as President and encouraging earnings results.
Merck (MRK): Stock to Gain on Likely Earnings Beat in Q4?
by Zacks Equity Research
We expect pharma heavyweight Merck & Co., Inc. (MRK) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Feb 2.
J&J to Acquire Actelion for $30B: Is It a Strategic Fit?
by Zacks Equity Research
Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Actelion (ALIOF) for $280 per share, as of Jan 25, 2017, in an all-cash transaction.
For $30 Billion, Johnson & Johnson is Acquiring Swiss Biotech Actelion
by Madeleine Johnson
On Thursday, healthcare giant Johnson & Johnson (JNJ) announced it will acquire Swiss biotechnology company Actelion for $30 billion in order to boost its roster of rare disease treatments.
Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft
by Zacks Equity Research
Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, reported mixed fourth-quarter 2016.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb
What Lies in Store for Pfizer (PFE) this Earnings Season?
by Zacks Equity Research
Pfizer Inc. (PFE) will be reporting fourth-quarter and full-year 2016 earnings results on Jan 31, before market open.
Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY
by Zacks Equity Research
How will these three drug stocks, CELG, BMY and BIIB, which are all scheduled to report Q4 results on Jan 26, fare this earnings season?
Is Customer Satisfaction the Hidden Key to Stock Outperformance?
by Eric Dutram
In this edition of the Dutram Report, we take a closer look at the idea of customer satisfaction. Do companies that serve their customers better end up being more impressive investments? In order to get to the bottom of this, I spoke with Kevin Quigg, Chief Strategist of ACSI Funds for some answers and insights.
Sunesis Offers Updates on SNS-062 and Qinprezo Programs
by Zacks Equity Research
Sunesis (SNSS) provided updates on two of its lead programs: SNS-062, and Qinprezo (vosaroxin).
Can AbbVie (ABBV) Spring a Surprise This Earnings Season?
by Zacks Equity Research
AbbVie Inc. (ABBV) is slated to release fourth-quarter and full-year 2016 earnings results before the opening bell on Jan 27.
Q4 Earnings Roundup: JNJ, VZ, MMM, DD, Etc.
by Mark Vickery
Ahead of the opening bell today, we have plenty of Q4 earnings results to report.
J&J (JNJ) Q4 Earnings Top; Seeks Options for Diabetes Unit
by Zacks Equity Research
Johnson & Johnson (JNJ) reported a mixed quarter with earnings beating expectations while sales missing the same.
The Zacks Analyst Blog Highlights: Goldman Sachs, DuPont, Johnson & Johnson, Verizon Communications and Travelers Companies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Goldman Sachs, DuPont, Johnson & Johnson, Verizon Communications and Travelers Companies
J&J (JNJ) Beats on Q4 Earnings, Sales Miss; Stock Down
by Zacks Equity Research
JNJ beat on fourth quarter earnings - the company reported EPS of $1.58 while our consensus called for EPS of $1.56.
The Best Earnings Charts on the Street
by Tracey Ryniec
It's not easy to beat on earnings every quarter for years but these companies are doing it.
Dow Stocks to Watch for Earnings on Nov 24: DD, JNJ, TRV, VZ
by Swarup Gupta
The nature of these releases is likely to determine the fortunes of the Dow in the days ahead.
Can Q4 Earnings Revitalize Healthcare ETFs?
by Sweta Killa
The Q4 earnings could bring some near-term relief given that the sector is expected to post earnings growth of 2.9% and revenue growth of 5.6%.
5 Best Performing Healthcare Mutual Funds of 2016
by Zacks Equity Research
Investors rely on the healthcare firms to safeguard their investments as demand for its services does not vary much with market conditions
J&J Arm Buys Megadyne, Boosts Electrosurgical Tools Portfolio
by Zacks Equity Research
Ethicon Endo-Surgery, Inc. a subsidiary of Johnson & Johnson (JNJ), announced the acquisition of Megadyne Medical Products, Inc., a privately held medical device company.
What's in Store for Abbott Labs (ABT) This Earnings Season?
by Zacks Equity Research
Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.